A three-judge panel on the 5th U.S. Circuit Court of Appeals sided with Louisiana in a lawsuit against the Food and Drug Administration (FDA). The court issued a temporary nationwide injunction that reinstates a 2021 nationwide requirement that mifepristone must be prescribed and dispensed in person.
Mifepristone is one of the two drugs commonly used in medication abortions.
The FDA permanently lifted the in-person requirement in 2023, leading to a surge in pills prescribed over the internet in the wake of the Dobbs ruling that overturned the constitutional right to an abortion.
Concerns are growing in southern California over a cluster of “exceptionally rare” cancer cases that has...
Donald Trump announced a new package of tariffs on Tuesday, this time on generic drugs made...
